Korean J Blood Transfus.  1999 Dec;10(2):239-243.

Unexpected Crossmatch-Incompatible Results by Anti-D in Intravenous Immune Globulin

Affiliations
  • 1Department of Clinical Pathology, Yonsei University College of Medicine, Seoul, Korea.

Abstract

A number of case report revealed the anti-D reactivity of intravenous immunoglobulin (IVIG). Passive transfer of anti-D activity through administration of IVIG has been implicated as cause of hemolysis in some reports. We have recently identified anti-D and anti-K in two pediatric patients with IVIG (Green corss, Korea) administration history whose red cells were both typed as D positive. One of them was 7 year old male and admitted for status epilepticus. and the other was 2 year old female with impression of Kawasaki disease. The anti-D in D positive patients and anti-K which is one of the least expected red cell alloantibodies considering the phenotypic profile of Kell group antigen in Korea were both thought to be passively transferred with IVIG. Eluate prepared from one of the two patients and diluted IVIG were test for the presence of irregular antibodies. Both tests revealed anti-D activity but not anti-K activity. Passive transfer of anti-D activity through administration of IVIG also has been implicated in hemolysis in some reports with suggestion to set an acceptable limit of anti-D titer for commercial IVIG preparations. The important aspects are what should be the appropriate specification for anti-D titer and what procedures used to measure the anti-D titer of the concentrated pure immunoglobulin preparations like IVIG products.


MeSH Terms

Antibodies
Child
Child, Preschool
Female
Hemolysis
Humans
Immunoglobulins
Immunoglobulins, Intravenous*
Isoantibodies
Korea
Male
Mucocutaneous Lymph Node Syndrome
Status Epilepticus
Antibodies
Immunoglobulins
Immunoglobulins, Intravenous
Isoantibodies
Full Text Links
  • KJBT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr